Later Stage HD Assessments (LSA)
Development of Assessments for Later Stage Huntington's Disease: UHDRS Structured Interview of Function and HD Clinical Status Questionnaire

Roche M[1], Cherneski, L[1], Handley OJ[2], Capodarca S[2], Frank S[3], Fuller R[1],
Orth M[4], Levey J[1], Neacy E[1], & Sampaio C[1].
[1]CHDI Management/CHDI Foundation, Princeton, New Jersey, USA
[2]European Huntington's Disease Network
[3]Beth Israel Deaconess Medical Center, Boston, MA, USA
[4]NeuroZentrum Siloah, Bern, Switzerland

Accelerating therapeutic development for Huntington's disease

Background

- Enroll-HD study is a longitudinal observational natural history study.
- While the full spectrum of Huntington's disease (HD) disease progression is represented in the Enroll-HD sample, there is an increasing number of participants in mid- and later stages of illness.
- As HD progresses, participants become increasingly dependent on caregivers and attendance at annual study visits becomes more difficult.
- Additionally, participant completed assessments that require motor or verbal responses may no longer be practical (as evidenced by increasing missing data) or valid (e.g., cognitive assessments).
- Therefore, there is a need to develop remotely delivered clinimetrically sound companion-report measures of HD-relevant domains.
- Currently, no such measures exist for the later stages of HD.
- To address this unmet need, CHDI has undertaken the development of two informant report measures: (1) Huntington's disease - Structured Interview of Function (HD-SIF) and (2) Huntington's Disease Clinical Status Questionnaire (HDCSQ).

Rationale

- Two assessments, HD-SIF and HDCSQ have been designed to capture disease milestones in mid- to later stage HD from companions of individuals with manifest HD, either in-person or remotely.
- The goal of creating the new assessments is two-fold:
  1) to provide the HD research and clinical community with improved outcomes for measuring disease stage and progression in later manifest stages of HD with the purpose of including these assessments in a large scale, global observational study of HD and/or other HD clinical studies as well as using them for planning clinical trials, and
  2) to determine whether these companion-reported assessments have comparable clinimetric properties when administered in-person and remotely.

Study objective

- To evaluate the clinimetric properties of the HD-SIF and the HDCSQ at the scale and item levels using the methods of Classical Test Theory (CCT) and Item Response Theory (IRT).



Study design

This is an observational study with two parts:

- Part 1 of this study will evaluate the reliability and validity of the HD-SIF (N= 20 participant-companion dyads) using CTT. It will take place at 4 US sites.
- Part 2 will assess the clinimetric properties of the HD-SIF and HDCSQ (N= 150 participant-companion dyads) using CCT and IRT. It will take place in 19 USA and UK sites.

Population

- Manifest HD Participants and Companion Participants will be invited to participate in either or both parts of this study.
- Manifest HD Participants must have a companion and meet the following criteria:
  - active participant in Enroll-HD study
  - Age ≥20 years
  - CAG repeat length ≥36
  - DCL=4
  - Inclusion score of ≥16 (inclusion score is a composite score based on UHDRS Functional Assessment Score and Total Motor Score; equivalent to TFC Stage III or greater)

Study sites



19 study sites based in the USA and UK
- Able to recruit at least 5 HD participant-companion dyads
- Rater available to complete training and administration of the HD-SIF

Study flow

Part 1



Study Site

Site visit
- HD Participant and Companion consent
- UHDRS '99 Functional Scales (Functional Capacity, Functional Assessment, and Independence Scale) with HD Participant & Companion; administered by Rater 1
- HD-SIF with Companion only; administered by Rater 2

Remote Study Visit (7-21 days later)
- HD-SIF with Companion only; administered by Rater 3

Remote Study Visit

Part 2



Study Site

Site visit
- HD Participant and Companion consent

Remote study visit
- HD-SIF
- HDCSQ

Remote Study Visit

LSA timeline

Part 1 sites: FPI 4Q 2021 -> LPI 1Q 2022
Part 2 sites: FPI 2Q 2022 -> FPI 2Q 2023
Analysis and finalization of scale development by end of 2023

LSA study team contacts

Selene Capodarca, Enroll-HD Global Project Manager
selene.capodarca@enroll-hd.org

Sandra Sellis and Nicola Robertson, LSA Study Managers (UK)
sandra.sellis@enroll-HD.org; nicola.robertson@enroll-hd.org

Priscila Winkowski, LSA Study Manager (USA)
priscila.winkowski@chdifoundation.org